Compare HOVR & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | IVVD |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 692.7M |
| IPO Year | N/A | 2021 |
| Metric | HOVR | IVVD |
|---|---|---|
| Price | $1.79 | $2.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.50 | ★ $8.33 |
| AVG Volume (30 Days) | 1.1M | ★ 12.1M |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | N/A | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $0.35 | $0.35 |
| 52 Week High | $4.18 | $3.07 |
| Indicator | HOVR | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 53.57 |
| Support Level | $1.16 | $2.09 |
| Resistance Level | $1.69 | $2.60 |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 68.98 | 16.33 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.